Peptide Receptor Radionuclide Therapy (PRRT) is a form of molecular targeted therapy that involves the systemic administration of a radiolabelled peptide that is designed to target receptors that are overexpressed on tumours. PRRT can be used to treat neuroendocrine tumours (NETs) by using radiolabelled somatostatin receptor agonist lutetium (177Lu) oxodotreotide.
The NCCP has designated St. Vincent’s University Hospital (SVUH) as the PRRT provider centre in Ireland. The PRRT service is operational since October 2023. The service at SVUH is expected to expand incrementally over the next 24 months. During this period, PRRT via the Treatment Abroad Scheme (TAS) will still be available until the service is fully operational in Ireland.
The following documentation will support the implementation of the service:
Peptide Receptor Radionuclide Therapy (PRRT) Patient Pathway
Peptide Receptor Radionuclide Therapy (PRRT) Service Specification
Patient Information Leaflet (PIL) Long
Patient Information Leaflet (PIL) Short
PRRT Tumour Conference Referral Form
PRRT National Tumour Conference SOP
